These results are similar to those described by Regan et al. [8], who recently analyzed the determinants for choosing chemotherapy in a population of hormone receptor-positive premenopausal patients enrolled in three different International Breast Cancer Study Group trials. This evidence concerns the gene NR4A1 and breast carcinoma.